



Texas Children's Hospital



BAYLOR
COLLEGE OF
MEDICINE

Department of
Pathology

Located in the Texas Medical Center

6621 Fannin Street
MC 1-2261
Houston, Texas 77030-2399
713 770-2250
Fax: 713 770-1032

One Baylor Plaza
Texas Medical Center
Houston, Texas 77030-3498
713-798-4432

Milton J. Finegold, M.D.
Director of Laboratories
Gregory J. Buffone, Ph.D.
Associate Director of Laboratories
Dawna L. Armstrong, M.D.
Neuropathology
Gretchen J. Darlington, Ph.D.
Tissue Culture & Molecular Biology
Gail J. Demmler, M.D.
Director, Virology
Wm. Michael Dunne, Jr., Ph.D.
Director, Microbiology & Serology
Vicky Gresik, M.D.
Director, Hematology & Blood Bank
Edith P. Hawkins, M.D.
Renal & Immunopathology
Hal K. Hawkins, M.D., Ph.D.
Electron Microscopy
Debra L. Kearney, M.D.
Cardiovascular Pathology
Claire Langston, M.D.
Director, Anatomic Pathology
Ching-Nan Ou, Ph.D.
Director, Clinical Chemistry & Toxicology
Hannes Vogel, M.D.
Neuropathology

May 4, 1992

Dr. Philip Migliore
Department of Pathology
Baylor College of Medicine
1 Baylor Plaza
Houston, TX 77030

Dear Dr. Migliore:

I would like to request a one year extension on my Moran foundation Grant #91-53. This project proposed to use the technique of in vivo footprinting by ligation-mediated polymerase chain reaction (LMPCR) to identify regions of the third component of complement (C3) gene that were important in its regulation. Unfortunately, due to other experimental commitments, I have been unable to devote sufficient time to move the proposed project to completion.

I have had the opportunity to learn the methodology outlined in the proposal. The results I have obtained thus far suggest that while footprinting by chemical modification of guanine residues (as outlined in the proposal) will allow me to detect certain of these regulatory regions, I will need an alternative approach(es) to identify regulatory regions of the DNA which occur in regions of low guanine content. Refinements to the procedure have been published since submission of the proposal; one of these uses DNase I sensitivity with subsequent LMPCR to expand the number of identifiable sites. This should be particularly useful in the case of the C3 gene since we have done numerous studies using DNase I footprinting in vitro; comparisons of the results obtained by the in vivo and in vitro approaches could therefore be made directly.

Thank you for your consideration.

Yours truly,

Deborah R. Wilson, Ph.D.



The Moran Foundation

DEPARTMENT OF PATHOLOGY
BAYLOR COLLEGE OF MEDICINE
TEXAS MEDICAL CENTER
HOUSTON, TEXAS 77030

May 12, 1992

Deborah R. Wilson, Ph.D.
Department of Pathology
Texas Children's Hospital
MC 1-2261
Houston, TX 77030

Dear Dr. Wilson:

Your request for a one year extension of your Moran Foundation project 1-91-0053 is approved. You may continue to draw on approved funds until June 30, 1993.

Our records indicate that \$8877.00 is still available. If this does not agree with your records, please let us know.

Sincerely yours,

Philip J. Migliore, M.D.
Research Director

PJM:lr

c: Dr. Michael W. Lieberman
Wes Moreland